Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 24, Issue 10, Pages 1009-1028Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2020.1805435
Keywords
Parkinson's disease; Alzheimer's disease; multiple Sclerosis; sigma receptors; neurological disease; multi-targeting drugs
Categories
Funding
- Rachadapisek Sompote Fund for Postdoctoral Fellowship, Chulalongkorn University
Ask authors/readers for more resources
Introduction The sigma receptors are found abundantly in the central nervous system and are targets for the treatment of various diseases, including Alzheimer's (AD), Parkinson's (PD), Huntington's disease (HD), depression, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). However, for many of these diseases, other receptors and targets have been the focus of the most, such as acetylcholine esterase inhibitors in Alzheimer's and dopamine replacement in Parkinson's. The currently available drugs for these diseases have limited success resulting in the requirement of an alternative approach to their treatment. Areas covered In this review, we discuss the potential role of the sigma receptors and their ligands as part of a multi receptor approach in the treatment of the diseases mentioned above. The literature reviewed was obtained through searches in databases, including PubMed, Web of Science, Google Scholar, and Scopus. Expert opinion Given sigma receptor agonists provide neuroprotection along with other benefits such as potentiating the effects of other receptors, further development of multi-receptor targeting ligands, and or the development of multi-drug combinations to target multiple receptors may prove beneficial in the future treatment of degenerative diseases of the CNS, especially when coupled with better diagnostic techniques.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available